Cisapride in children with chronic intestinal pseudoobstruction. An acute, double-blind, crossover,

C Di Lorenzo1, S N Reddy, J Villanueva-Meyer

  • 1Department of Pediatrics, Harbor-UCLA Medical Center, Torrance.

Gastroenterology
|December 1, 1991
PubMed

Insights

Cisapride improved duodenal motility in children with chronic intestinal pseudoobstruction but did not enhance gastric emptying. This study assessed cisapride

Area of Science:

  • Pediatric Gastroenterology
  • Gastrointestinal Motility Disorders

Background:

  • Chronic intestinal pseudoobstruction (CIPO) significantly impacts children's quality of life, often necessitating specialized feeding.
  • Understanding the effects of prokinetic agents like cisapride is crucial for managing CIPO symptoms.

Purpose of the Study:

  • To evaluate the efficacy of cisapride in improving gastrointestinal motility and gastric emptying in pediatric patients with CIPO.
  • To determine if cisapride can positively influence the severe motility abnormalities characteristic of CIPO.

Main Methods:

  • A double-blind, randomized crossover study involving 20 children with CIPO.
  • Utilized antroduodenal manometry to record motility and 99mTc-labeled meals to assess gastric emptying over 5 days.
  • Administered cisapride (0.3 mg/kg t.i.d.) or placebo with a 2-day washout period.

Main Results:

  • Cisapride significantly increased the postprandial duodenal motility index (P < 0.05).
  • No significant effect of cisapride was observed on antral motility.
  • Cisapride did not alter the delayed gastric emptying, with no significant changes in T1/2 or R60.

Conclusions:

  • Cisapride enhances postprandial duodenal motility in children with CIPO.
  • Cisapride does not improve the significant delay in gastric emptying observed in these patients.
  • Further research may be needed to explore alternative treatments for gastric emptying issues in pediatric CIPO.

Related Concept Videos

Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists01:28

Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists

Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...
1.9K
Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists01:23

Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists

Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
1.4K
Drugs for Treatment of Diarrhea-Predominant IBS01:17

Drugs for Treatment of Diarrhea-Predominant IBS

Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
950
Drugs for Treatment of Constipation-Predominant IBS01:21

Drugs for Treatment of Constipation-Predominant IBS

Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
1.4K
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists01:27

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
910
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists01:29

Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists

Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
1.2K